Get access

Substitution with doxorubicin for daunorubicin during induction for high risk pediatric acute lymphoblastic leukemia results in increased toxicity

Authors

  • Rebecca A. Gardner MD,

    Corresponding author
    1. Division of Pediatric Hematology/Oncology, Seattle Children's Hospital, Seattle, Washington
    2. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
    3. Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington
    • M/S OL-1, PO Box 5371, Seattle, WA 98145.===

    Search for more papers by this author
  • Blythe Thomson MD,

    1. Division of Pediatric Hematology/Oncology, Seattle Children's Hospital, Seattle, Washington
    2. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
    3. Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington
    Search for more papers by this author
  • Douglas S. Hawkins MD

    1. Division of Pediatric Hematology/Oncology, Seattle Children's Hospital, Seattle, Washington
    2. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington
    3. Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington
    Search for more papers by this author

No abstract is available for this article.

Ancillary